Mounjaro (Tirzepatide) is a new weight-loss drug that has gained attention for its effectiveness in managing both type 2 diabetes and obesity. It has launched by global pharmaceutical company Eli Lilly in India.
As per media reports, Mounjaro is a single-molecule drug designed to bind to and activate both GIP and GLP-1 receptors, helps in regulating regulate blood sugar and metabolism.
Approved by the Central Drugs Standard Control Organisation (CDSCO), the once-weekly injectable drug offers a novel approach to metabolic health management, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Mounjaro is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve blood sugar control. It is also prescribed for chronic weight management in individuals with a body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) with at least one weight-related condition.
As per a report in the Times of India, Mounjaro is available in India in single-dose vials, with pricing starting at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial. Monthly treatment costs range between Rs 14,000 and Rs 17,500, depending on the dosage.
As per medical experts, Mounjaro suppresses appetite and makes you feel more full. It changes the rate at which your stomach empties.
